source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Horizon Discovery and Rutgers University form exclusive partnership to develop novel next-generation gene editing technology

Horizon Discovery Group logo 30.1.19Rutgers University logo 30.1.19Horizon Discovery Group plc, a specialist in gene editing and gene modulation technologies, has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey, to develop and commercialise a novel gene editing technology known as base editing. The technology potentially has applications in the development of new cell therapies and Horizon stated that it would augment the company’s research tools and services.

Horizon will collaborate with Rutgers to further develop the novel base editing platform from the laboratory of Dr Shengkan Jin, associate professor of pharmacology at Rutgers Robert Wood Johnson Medical School. Horizon has made a non-material payment to Rutgers for an option to exclusively license the technology for use in all therapeutic applications. Horizon will also fund further research in base editing at Rutgers while undertaking evaluation and proof-of-concept studies at Horizon.

Base editing is a novel technology platform for engineering DNA with the potential to correct errors or mutations by modifying genes using an enzyme. Compared with currently available gene editing methodologies such as CRISPR/Cas9, which creates ‘cuts’ in the gene and possibly lead to adverse or negative effects, this new technology allows for more accurate gene editing while reducing unintended genomic changes. Horizon says the technology will have a significant impact in enabling cell therapies to be progressed through clinical development and towards commercialisation.

For further information about Horizon Discovery Group plc visit www.horizondiscovery.com and for further information about Rutgers University visit www.rutgers.edu 

Last modified onFriday, 01 March 2019 08:02